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Abstract
Background: Rare diseases, also referred to as orphan diseases, are characterised by their low prevalence with
majority of them are chronically debilitating and life threatening. Given the low prevalence and the widely
dispersed but very small patient base for each disease, there may often be a disproportion in the availability of
treatments and resources to manage patients, spur research and train experts. This is especially true in Southeast
Asian countries that are currently in the process of implementing or revising their universal health coverage
schemes. This paper aims to examine the status of rare disease management in Southeast Asian countries. It will
serve as the basis for a more active discussion on how countries in the region can address an under-recognised
rare disease burden and enhance national and regional capacities.
Methods: The study consists of literature reviews and key stakeholders interviews in six focus countries, including
the Philippines, Singapore, Malaysia, Indonesia, Vietnam, and Thailand and five countries as best practice,
comprising of France, Canada, Australia, Taiwan, and South Korea. Rare disease management initiatives across each
country were examined based on the World Health Organization’s framework for action in strengthening health
systems.
Results: The results suggest rare disease management remains challenging across Southeast Asia, as many of the
focus countries face fundamental issues from basic healthcare systems to funding. Nonetheless, there are substantial
improvement opportunities, including leveraging best practices from around the world and organising a
multi-stakeholder and regional approach and strategy.
Conclusions: Southeast Asian countries have made significant progress in the management of rare disease, but there
remain key areas for substantial development opportunities.
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Background
The state of rare diseases
Rare diseases are serious and can be life threatening. Even
where treatment is available, the disease will likely be a
lifetime condition for the patient. While they are charac-
terised by their rarity (less than 1:2000 in Europe, 1:1500
in United States of America, or 1:2500 in Japan), they can
collectively affect 1 in 15 persons worldwide [1, 2]. There-
fore, while the prevalence of rare diseases in each country
is low, total number of people who suffer from rare
diseases could be about 400 million worldwide [2]. It is
important to note that the prevalence of rare diseases var-
ies based on the type of disease, with some rare diseases
affecting 1:100,000 people or less [1]. This rarity heightens
the isolation and limited treatment that patients with rare
diseases often face.
Despite being “rare,” in Southeast Asia, over 45 million
people, or about 9 % of the region’s population, suffer
from rare diseases [3]. This number remains contested
and it could be even higher. Research and active monitor-
ing of rare diseases is not a priority in Southeast Asia
largely due to a lack of resources and inadequate funding.
As such, mysterious child deaths in the region may have
underlying genetic correlations thus under-reporting the
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true burden of disease. Out of the eight thousand rare
diseases currently characterised in the world, it is likely
that several of these rare diseases occur more regularly
amongst Southeast Asian populations. For example,
Moyamoya disease, which is recognised as a global
pathology predominantly affecting children and young
adults, is largely present amongst Asian ethnicities [4].
Given the lack of epidemiological data, rare disease
landscape and management remain unclear throughout
the region. While Southeast Asian countries have made
noticeable progress towards universal health care cover-
age, the focus has been on primary preventive care and
acute care [5]. Consequently, funding for rare disease
research and treatments remains a central challenge.
Rarity of diseases limits understanding and appropriate
healthcare provision
Due to the limited number of individuals affected by a rare
disease, there is lack of experience in managing rare dis-
eases within the local community. Many cases unfortu-
nately result in initial misdiagnosis or failure to diagnose,
inadequate treatments, or lack of available treatments [6].
Moreover, without intervention or incentive by the regula-
tory bodies, pharmaceutical industry may not have the
economic motivations to develop treatment for rare
diseases given the high cost and small patient base. As
such, due to their largely neglected status, pharmaceut-
ical treatments for rare disease t are also call as “orphan
drugs.” Because orphan drugs can be expensive and low
on public health priority (low prevalence), they were
often not reimbursable through public fund. Hence, pa-
tients with rare diseases may appear marginalised as
most of the funding for their treatment may come from
out of pocket, public-private partnerships, charitable
organisations, and industry groups (patient assistance
programmes) [7]. Moreover, due to the limited under-
standing and medicinal support, patients may often feel
socially and psychologically isolated [6].
Progress in public awareness and investment opportunities
Public awareness and investment opportunities for rare
diseases have increased in recent decades, largely be-
cause of work done by patient support groups and The
Orphan Drug Act in 1983 in the United States. The
Orphan Drug Act creates financial incentives for the
research and production of orphan drugs, including tax
incentives, patent protections, and clinical research sub-
sidies [8]. Following this enactment, there was a noticeable
increase in the number of designated and approved orphan
drug by U.S. Food and Drug Administration every decade;
from year 1983 (2), 1993 (90), 2003 (238) until 2013 (439)
[9]. Continued efforts from the United States spurred the
Rare Diseases Act in 2002, establishing an Office of Rare
Diseases as a federal entity and increasing national research
and investment in the development of diagnostics and
treatments for patients with rare diseases [10]. Other
countries have followed suite by introducing their own
legislation recognising orphan drugs in the past two
decades, including Singapore (1991), Japan (1993),
Australia (1997), Taiwan (2000), Europe (2002) and
South Korea (2003). Despite the progress of orphan
drugs and rare disease legislation in some of the coun-
tries, disparities remain in the availability of effective
treatment for rare diseases globally due to the lack of
scientific knowledge and financial incentives. Hence,
one of the central suggestions by the World Health
Organization in the recent Priority Medicines Report
2013 is to prioritize orphan drugs, by developing new
mechanisms to promote the development of basic rare
disease research into important treatments [2].
Given the current environment and complexities, the
need to understand rare diseases in Southeast Asia is im-
perative in order to offer suggestions on how the region
can better tackle rare diseases and potentially improve
healthcare on both a country and regional level.
Method
Study setting
In this report, we will review the state of rare disease man-
agement in Southeast Asia around several key themes and
benchmark them against best practice countries. We have
chosen to focus on the six major countries of Southeast
Asia: the Philippines, Singapore, Malaysia, Indonesia,
Vietnam, and Thailand. These countries were specifically
selected on the grounds of economic development,
fairly developed national health programmes, and a
capacity for regional cooperation and openness. As best
practice countries, we have reviewed corresponding
rare disease management in five countries: France,
Canada, Australia, Taiwan, and South Korea. We have
designated these countries as best practice, as key opin-
ion leaders most frequently referenced them and their
experience were widely reported in existing literature.
Data sources
We used multiple sources to obtain relevant information
related to rare diseases according to the selected themes.
We employed the World Health Organization’s frame-
work for action in strengthening health systems within
which to review the status of rare disease management in
the focus countries [11]. To supplement the World Health
Organization’s evaluation, we reviewed key literature and
conducted stakeholder interviews with clinicians, policy-
makers, advocacy groups, and pharmaceutical experts.
The primary and secondary research identified six core
themes that were used as criteria for evaluation across the
focus geographies and best practice countries.
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A comprehensive literature review was performed in
June 2014 using electronic databases (PubMed, Google
Scholar), published policy documents, and Ministry of
Health websites using directed search requests. In
addition, supplementary themes were also explored on
the management and regulatory requirements of or-
phan drugs in target benchmark countries. Key opinion
leaders were identified through government channels
and expert connections. This group included clinicians,
policymakers, advocacy groups, and industry leaders.
They were consulted using a semi-structured interview
approach to improve the understanding of local and re-
gional rare disease issues. The semi-structured interview
guide focused on four main issues: i) governance: defin-
ition, national strategy or plans, physicians’ involvement,
research on rare disease; ii) access: access for the treat-
ment and orphan drugs, support programmes, public
awareness; iii) infrastructure: clinical practice guidelines of
rare disease, patient registries, neonatal screening pro-
grammes, and centre of expertise; and iv) opportunities:
training, capacity-building projects, support group, and
any strategies suggested.
Analysis
Information was extracted according to six themes. These
themes were used as anchors to identify and assess the
national initiatives of rare diseases in the six Southeast
Asian geographies as well as the best practice countries.
The assessment criteria included:
1. Healthcare system
2. Governance
3. Patient advocacy and rare disease awareness
4. Clinical expertise and patient management
5. Funding
6. New-born screening of rare diseases
Additional insights were captured from the comprehen-
sive literature reviews and interviews of key opinion
leaders. The results are presented in Table 1 and discussed
in further detail in the following section.
Results
In general, the six focus countries in Southeast Asia
have made healthy progress towards rare disease man-
agement. However, the progress differs widely across
the themes and region (Table 1). For example, Singapore
has a mature health system and several disease awareness
initiatives but limited rare disease legislation or funding.
On the other hand, the Philippines falls short relative to
its peers in terms of health capacity and health expend-
iture, but it is the first country in the region to introduce a
national strategy specifically for rare disease management.
In the following, we observe the results for each theme,
highlighting countries’ progress and shortcomings.
Healthcare system
The effectiveness of a country’s healthcare system is con-
sidered an important factor for successful development of
rare disease management. An effective healthcare system
establishes strong foundations for healthcare capacities,
capabilities, and budgetary decisions in a country. The six
focus geographies differ significantly in their provision of
health capabilities and financing, in large part driven by
the heterogeneity of economic systems across the region.
Singapore has the highest GDP per capita (USD 54,007),
health care expenditure (USD 2426), and out-of-pocket
expenditure (58.6 %) [11]. This translates to a relatively
comprehensive health care coverage for their citizens, low
infant mortality rate (1.8 per 1000 live births), and a life
expectancy of 82 years. In contrast, Vietnam has the low-
est GDP per capita (USD 1775), low health expenditure
per capita (USD 103), and a high mortality rate (19.5 per
1000 live births). While economic prosperity may be a
strong indicator for a country’s healthcare system, it may
be a fallacy that countries must attain economic prosperity
before addressing the challenge of rare diseases. Taiwan
and South Korea were not top tier income nations before
comprehensive support was implemented for rare dis-
eases, a trend apparently replicated in Southeast Asia.
Malaysia and the Philippines both have lower GDP per
capita (USD 10,440 and USD 2588, respectively) and
health care expenditure per capita (USD 119 and USD
410, respectively), however, they either have a rare disease
national plan (the Philippines) or are in the process of
drafting one (Malaysia).
In addition to the healthcare capacity, the region is also
characterised by a range of different healthcare financing
schemes with various degree of the potentially cata-
strophic out-of-pocket payments. Singapore recorded the
highest out-of-pocket expenditure (58.6 % of total expend-
iture on health) for health care while Thailand is the least
(13.1 %). However, most of the countries have made sig-
nificant progress in reducing out-of-pocket health spend-
ing. This progress has been analogous with most countries
reviewing and strengthening their universal healthcare
coverage.
While a country’s financing method and total spending
are not by themselves indicators of better health out-
comes or achievements in rare disease legislation, it is
certainly an important factor that underscores how
much attention can be given to rare diseases, assuming
other health crises have been sufficiently addressed.
Governance
Effective governance is another important factor for rare
disease management, as it can guide a country’s national
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Table 1 National initiatives to support rare diseases and access to orphan drugs
Indicator Philippines Singapore Malaysia Indonesia Vietnam Thailand
Health system GDP per capita (USD) 2,588 54,007 10,440 3,551 1,755 5,480
Health expenditure per capita (USD) 119 2,426 410 108 103 215
Total health expenditure (% of GDP) 4.6 4.7 3.9 3.0 6.6 3.9
Health coverage (%) [37] 76 100 100 48 55 98
Out of pocket health expenditure (% of total
expenditure on health)
52.0 58.6 35.6 45.3 48.8 13.1
Life expectancy at birth (years) [40] 69 82 75 70 73 75
Mortality rate, infant (per 1,000 live births) [40] 22 1.8 7 32 16 11
Governance Presence of national strategy Yes No In progress No No No
Definition of rare disease Yes Yes Yes No No No
Comprehensive rare disease legislation Yes (2015) No No No No No
Orphan drug act/ legislation Pending approval Yes (1991) No No No No
Awareness Patient support/advocacy groups PSOD RDSS MLDS, MMA, MRDS No NPH RD
club
Genetic LSD Foundation
Patient support group activity Yes
(since 2010)
Yes
(since 2013)
Yes
(since 2010)
No Yes
(since 2013)
Yes
(since 2011)
Media attention (Based on Factiva
search from 2009–2015)
72 articles 48 articles 33 articles 13
articles
26 articles 12 articles
Clinical
expertise
Presence of patient registries Largely institution specific No No Planned, LSD diseases
Presence of centre of expertise Yes (1) Yes (2) Yes (3) No Yes (1) Yes (2)
Presence of national guidelines for treatment No No No No No No
Professional societies to support specialist No No Limited No No No
Funding Government funding for rare disease treatments Limited Limited Limited No No Limited
Government funding for rare disease research No Yes No No No No
Non-government access to rare disease
treatment
Some charitable and
industry funds
Some charitable and
industry funds
Some charitable and
industry funds, employer
benefits
No No Some charitable and
industry funds
New born
screening
National neonatal screening programs Yes Yes Yes No Yes Yes
Percentage of new born screened 28 % 100 % >95 % <1 % 31 % >97 %
Source of payment for the new born screening OOP/insurance OOP (40 %) Gov./ OOP OOP Government
Abbreviations: OOP Out of Pocket, Gov Government, PSOD Philippine Society for Orphan Disorders, RDSS Rare Disorders Society (Singapore), MLDA Malaysia Lysosomal Diseases Association, MMA Malaysian Medical
Association, MRDS Malaysian Rare Disorders Society, NPH RD National Pediatric Hospital (rare disease), LSD Lysosomal storage diseases
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strategy and create legislation for rare diseases and or-
phan drugs. On this criterion, there are marked differ-
ences among the six focus countries.
In the region, only the Philippines has a national strat-
egy specifically for rare disease management. The Rare
Disease Act of the Philippines was approved in September
2015, covering many key elements including rare diseases,
orphan drugs, patients’ care, registry, research and devel-
opment, information sharing, and screenings [12]. Most
importantly, the act categorises patients with rare diseases
as ‘persons with disability,’ thus allowing patients to bene-
fit from the statutory benefits provided for in the Republic
Act 9442, including discounts on healthcare services and
medicines [13].
Other countries are gently advancing their rare disease
strategies as well. Malaysia is in the process of develop-
ing a national framework for rare disease management.
It is currently creating this framework through coordin-
ating national activity, promoting multidisciplinary clin-
ical care of patients and improving on-time diagnosis
and treatment. This initiative comes after the govern-
ment included orphan drugs as one of the elements of
the National Medicine Policy in 2012 [14]. Similarly,
Singapore adopted the Orphan Drug Act in 1991,
expanding drug management by creating a legal frame-
work and promoting the supply of orphan drugs [15].
However, Singapore did not include any financial incen-
tives or additional support for patients, largely due to
budgetary concerns.
While transitioning from middle-income status in 2000,
Taiwan enacted the Rare Disease and Orphan Act. The
act included financial subsidies and exclusive marketing
rights for orphan drugs for 10 years [16]. Ten years
after implementing the act, the Taiwanese government
officially approved 184 rare diseases with 74 orphan
drugs and 40 special nutrients. The number of rare
disease patients had also increased from about 4200
people (2004) to more than 6000 people (2011). More-
over, all Taiwanese rare disease sufferers are eligible to
get at least 70 % reimbursement on orphan drugs,
whereas low-income citizens can receive 100 % reim-
bursement [17]. This made Taiwan as one of the best
practice model of comprehensive rare disease manage-
ment governance.
Effective governance is critical to the development of
rare disease management; however, it is important to
underline that the government is not the only key
player in pushing forward a strategy for rare disease
management. In the Philippines, the Rare Disease Act
approved in September 2015 has strong backing from
patient support groups who took initiatives to map out
the national strategy [18]. Additionally, in Taiwan, the
advocacy groups also strongly support rare disease pa-
tients and the country legislation.
Patient advocacy and rare disease awareness
Awareness is a critical factor in rare disease management
as it leads to greater public and private involvement. Over
the past 5 years, public awareness of rare diseases has
increased in Southeast Asia. Most of the focus countries
(except Indonesia) have their own patient support groups
such as the Philippine Society for Orphan Disorders
(the Philippines), Rare Disorders Society (Singapore),
Malaysian Rare Disorder Society (Malaysia), and Genetic
LSD Foundation (Thailand). Beside information from
their doctors, the patients can search and get more infor-
mation from these societies in their country. Like other
countries, these groups involved in many rare disease ac-
tivities. They hosting an awareness campaign and local
rare disease conference, produce traditional and new
media such as television programmes, publications and
blogs as well as social media (Facebook). Every year they
organise rare disease day, charity run, fundraising and do-
nation. To sustain the networking with others, they also
participate especially in rare disease meetings and confer-
ences locally as well as around the world [19–21]. Their
efforts have resulted in strong media attention in the
Philippines, Singapore, and Malaysia, based on hit rates
more than 30 in the Factiva search conducted as part of
the study.
In particular, the Philippines reports strong support
and activity from patient and advocacy groups. The
primary group, Philippine Society for Orphan Disor-
ders, had drafted the national rare disease strategy for
the Philippines and is a core proponent of the recently
approved legislation, the Rare Disease Act of the
Philippines (2015) [18].
Singapore may also now increase public awareness, as
it hosted the first Rare Disease Asia Conference in
February 2015. The conference brought together 25 pa-
tient support groups from 13 countries. Moreover, it
has established the Rainbow Across Borders patient sup-
port organisation that acts as a regional umbrella alliance
for rare diseases [22]. This organisation promotes regional
collaboration and networking among patient support or-
ganisations from countries within the Asia-Pacific region.
Its objectives are to empower patient support organisa-
tions through appropriate programmes, services and train-
ing, while facilitating learning, and experience exchange
among the affiliates. The organisation also focuses on
developing the rare disease registry and directory across
Asia.
Overall, the existence of patient advocacy across
Southeast Asia is a positive sign and highlights the se-
verity and pressing need to tackle the challenge of rare
disease management. Southeast Asian groups could emu-
late the practice and model of other patient advocacy
group in reference country like Australia. Over 200 rare
disease patient organisations are unified under Australia’s
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National Alliance for rare diseases, named Rare Voices
Australia (RVA) [23]. RVA is established in 2012, which
provides a strong common voice to promote for health
policy and a healthcare system that works for those
with rare diseases. It also work with a vast range of
stakeholders including Federal and State governments, re-
searchers, health professionals and industry to promote
and advocate for equity within the health care system.
Clinical expertise and patient management
Clinical expertise and patient management of rare dis-
eases varies widely across the region, need to be im-
proved. For example, patient registries are critical in
the management of rare diseases; however, there are no
national rare disease patient registries in the region. Ra-
ther, most countries have separate lists or databases in
individual institutions or treating facilities. This leads
to potential risks such as redundant entries of patients,
producing incomplete data on the prevalence of rare
diseases. No country has proposed improvements, ex-
cept for Thailand who plans to create a nationwide
database of lysosomal storage diseases.
In addition, there is a lack of clinical rare disease ex-
pertise across the region. There are only a limited num-
ber of genetic specialists and only a few institutional
centres that offer specific services to treat rare diseases.
For example, in Thailand, there are only 22 geneticists
available to serve the whole population of 67 million
people, with most of them located in major cities. More-
over, there is no professional society focused on rare dis-
eases to support those specialists, collecting and sharing
local experiences. As a result, genetic specialists often do
not have the critical mass to influence the direction of
funding and availability of specialised care.
In 2014, Care for Rare, a pan-Canadian research team
has developed an online database named Phenome Central.
It is created as a hub to bring doctors and scientists work-
ing on rare diseases together [24]. This online database is
a great initiative to help clinicians and rare disease sci-
entists all over the world to share their case records
and information in the database, which can be used by
rare disease clinicians in SEA region.
Funding
Funding in rare diseases is central to the discussion of
rare disease management and reaches across key stake-
holders, including patients, the government, and the pri-
vate sector. Due to high cost of treatment for relatively
few individuals, there are often worries that coverage of
rare diseases will undermine the financial sustainability
of private investment as well as a country’s universal
healthcare coverage. Government funding for rare dis-
ease treatments is limited and ad hoc across Southeast
Asia. Only a small number of patients have access to
treatment. For example, the Malaysian government sub-
sidises only certain enzyme replacement therapies and
treatments such as alglucosidase alfa and elaprase.
Moreover, this limited funding is only available for se-
lected patients meeting a number of selective criteria for
eligibility and only through hospitals run by the Ministry
of Health [25]. Nonetheless, Malaysia is one of the few
countries offering some form of public funding for rare
diseases. In other countries, the large majority of rare
disease financing is through industry subsidisation, em-
ployer benefits, charitable work or out-of-pocket pay-
ment. In Singapore, only a few rare disease patients
receive subsidies from the industry, hospital funds, or
Medifund, the national means-tested fund for indigent
patients.
Another issue in the region is there is no systematic
mechanism for rare disease funding and rather, a sporadic
and inconsistent use of cost assessment frameworks to
guide funding decisions. According to National Institute
for Health and Care Excellence guidelines, a medical
treatment is considered cost effective if the incremental
cost-effectiveness ratio is below GBP 30,000 per quality-
adjusted life year gained [26]. By using this method,
most orphan drugs are unlikely to be cost-effective. For
example, treatment for infantile Pompe disease has an
incremental cost-effectiveness ratio estimated at GBP
1,000,000, which is more than 30 times higher than the
threshold [27]. For this reason, a fit-for-purpose process
is needed which may consider other factors in addition
to its cost-effectiveness. In Thailand, the ceiling
threshold of incremental cost-effectiveness ratio is
below THB160,000 per quality-adjusted life year. Yet,
for Type 1 Gaucher disease, there were budget impacts
and equity issues that rendered it a positive economic
choice, despite the unattractive ICER (THB6,300,000
per quality-adjusted life year or 50 times greater than
the cost-effectiveness threshold) [28]. This success is
expected to heighten awareness of funding authorities
throughout the SEA region.
The message is that by concentrating on costs and its
cost-effectiveness only, we will miss the broader picture
behind the rare diseases management and equitable
access to healthcare. Thailand’s example may provide
opportunities for other orphan drugs to be reimbursed
as well. Furthermore, only small percentage of total
health expenditure are allocated for rare disease treat-
ment compared to other diseases; for example Europe
and United States spends about 3.3 and 7.7 % respect-
ively [29, 30].
New-born screening of rare diseases
The onset of rare diseases typically occurs in children for
50 % of rare diseases [6]. It is therefore a common proced-
ure in most health facilities to screen newborn babies for
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selected congenital illnesses amenable to early interven-
tion and treatment. Early intervention helps to prevent
serious problems, as some medical conditions are indis-
cernible. Each of the focus countries, with the exception
of Indonesia, has an established newborn screening policy
with various degrees of funding, participation and imple-
mentation. In addition, the lack of access to reliable neo-
natal testing facilities and a limited number of specialists
contribute to the delay of diagnosis. Many of the rare dis-
ease tests also must be sent abroad for analysis, which
adds to the total cost of treatment.
In the Philippines, a new-born screening centre was
established in 1997 to serve as the central laboratory that
providing advanced tests for the National Comprehensive
New-born Screening System [31]. Even though the
National Neonatal Screening Plan is in place, the ap-
proximately USD 12 out of pocket cost of neonatal
screening is still a burden for many poor families as
the annual income of Filipinos was less than USD
5000 per annum or around USD 13.7 per day in 2012
[32, 33].
New-born screening began in Malaysia in 1980 with
cord-blood screening for glucose-6-phosphate dehydro-
genase deficiency [34]. Many of the newborn tests how-
ever are not mandatory including amino acid metabolism,
fatty acid oxidation, and organic acid metabolism disor-
ders. Malaysia expanded newborn screening which in-
cluded inborn errors of metabolism. Nevertheless, the
expanded tests are only available mainly in two centres
(Institute for Medical Research and Centre for Advanced
Analytical Toxicology Services) at the request by public
hospitals and some private hospitals [34]. Additionally,
Malaysia still faces a dearth of information and resources,
which reduces the uptake of the newborn screening pol-
icy; these include a limited number of specialists and the
perception among parents that new-born screening is
optional.
Singapore provides more than 25 metabolic related
screening tests for newborn babies under the National Ex-
panded New-born Screening Programme. The programme
offers screening of inborn errors of metabolism to all ba-
bies born in Singapore [35]. Nevertheless, more complex
tests including lysosomal storage diseases are still sent to
Japan and Taiwan as they have the only screening facilities
for these types of disorders in Asia [36].
Discussion
From the broad overview of rare disease initiatives across
the focus countries in SEA, we have developed the follow-
ing observations and recommendations:
1. Rare disease management remains immensely
challenging across the region, as costs remain high
and resources are limited.
2. Countries in SEA are largely disparate in the
advancement of rare disease management.
3. There are substantial improvement opportunities
across all aspects.
4. It is important for each focus country to adopt and
adapt best practices from around the world.
5. There is potential to organise a multi-stakeholder
and multi-country approach and strategy to manage
rare diseases efficiently.
The observations and recommendations highlight the
opportunities for the region to leverage best practices
within SEA and worldwide, in order to improve rare
disease management on a country and regional level.
However, the six focus geographies face huge challenges
and thus, the effort should be on making incremental
steps towards a regional model to manage rare diseases
efficiently.
Rare disease management remains immensely
challenging across the region, as costs remain high and
resources are limited
There are major barriers toward effective rare disease
management worldwide. The challenging nature of rare
diseases, most notably their low incidence rate, renders
management difficult as the average annual cost per per-
son works inverse to prevalence. Moreover, the increasing
number of orphan drugs and budget impact continue to
concern decision makers. As such, governments world-
wide face a problem in prioritising funding for orphan
drugs. In particular to Southeast Asia, over 45 million
people in the region are estimated to suffer from rare dis-
eases [3]. However, Southeast Asia also shoulders other
health challenges (e.g. cardiovascular disease) that are
more common, and therefore more publicised. With fewer
resources than those in many other areas of the world, the
region has historically focused its health policy on ensur-
ing primary and preventive care, acute care, and manage-
ment of disease with high epidemiologic burden. The
concentration on broadening access in such areas under-
standably leaves little room for funding, let alone discus-
sions, on rare diseases. Despite limited prioritisation,
horizontal and vertical equity arguments from various
stakeholders, including patient advocacy groups, have ele-
vated the need to tackle rare diseases across the region.
We can accordingly observe that Southeast Asian coun-
tries consider rare diseases initiatives as in scope and sali-
ent, although current efforts are fragmented and dispersed
across the region.
Countries in southeast Asia are largely disparate in the
advancement of rare disease management
While there are positive advancements throughout
Southeast Asia, barriers remain and health systems differ
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widely across borders. Across the region, growing aware-
ness of rare diseases is grounded on patient support and
advocacy groups. In all of the focus countries, excluding
Indonesia, there is at least one active patient support
group, along with the regional alliance for rare diseases,
Rainbow Across Borders. Despite this, there remain per-
sistent limitations, including inadequate funding, lack of
clinical expertise, and patient management.
With regard to the health system and governance, the
six focus countries differ remarkably. Singapore spends 20
times more on health per capita than Vietnam, Indonesia,
and the Philippines [33]. In addition, Singapore covers
100 % of its population, while Indonesia, Vietnam, and the
Philippines have significantly lower health coverages (48,
55, and 76 %, respectively) [37]. Despite this, the
Philippines has made tremendous progress in formulating
their rare disease national strategy, including a national
definition of rare disease and comprehensive rare disease
legislation. It included management of persons with rare
diseases, designation of rare disease and orphan drug, role
of agencies and incentives for rare diseases [12]. While
Singapore Orphan Drug Act has gazetted only manage-
ment and supply of orphan drug information [15]. There
is no formal governance structure for rare disease in
Thailand, Vietnam, and Indonesia. Except for Indonesia,
the other focus countries have an established national
neonatal screening programme with various degree of par-
ticipation. While Singapore and Thailand screen more
than 97 and 100 % of their new-born babies respectively,
the Philippines and Vietnam only screen 28 and 31 %, re-
spectively [36].
There are substantial improvement opportunities across
all aspects
Southeast Asia faces significant gaps across the rare
disease management themes. With regard to the over-
arching health system, resources, outcomes, and fund-
ing differ widely, with most of the region prioritising
chronic and communicable diseases. Given this, there
may be muted political will and commitment to support
rare diseases. While strong patient advocacy groups exist,
the lack of patient registries with standardised information
renders understanding the situation in the region difficult.
In addition, there is a lack of infrastructure to support
medical care intervention and limited standardisation of
guidelines for treatment. Finally, the region also sees in-
equitable funding for treatments, with a strong perception
that coverage of rare diseases will undermine the financial
sustainability of current basic universal coverage systems.
Given these complexities, the focus geographies could
substantially improve and develop stronger rare disease
management platforms consisting of advocacy and aware-
ness promotion, partnerships and sharing within and be-
tween countries, support for rare disease research, and
holistic funding models. This could be developed with the
combined effort of patients, families, and physicians,
working with advocacy groups to help increase public and
political awareness. In addition, countries could share
available information for clinicians, researchers, and pa-
tients. Finally, it is feasible and crucial for the region to
adopt and adapt best practices from around the world,
and develop partnerships and regional cooperation across
Southeast Asia and internationally.
It is important for each focus country to adopt and adapt
best practices from around the world
To develop a good national rare disease plan is not an
easy task for many countries. Some other countries typ-
ically take a long journey from decision to elaborate a
national rare disease plan to full or even partial imple-
mentation. Even many benchmark countries like Australia
and Canada also have yet to reach the end of path (Fig. 1).
Therefore, cooperation with regional and international is
essential in rare disease management. SEA countries can
adopt and adapt the best established practices and ap-
proaches from benchmark countries. A critical fallacy
to be corrected is that countries must attain economic
prosperity before focusing on rare diseases. For exam-
ples, Taiwan and South Korea were not top tier income
nations before comprehensive support to rare disease
was implemented.
Again, Taiwan is a good example of what is possible.
The Rare Disease and Orphan Drug Act 2000, has
enshrined special pricing rules and regulations. After
10 year of its implementation, the Taiwanese govern-
ment officially approved 184 rare diseases with 74 or-
phan drugs and 40 special nutrients [16]. Number of
rare disease patients has also increased from about
4200 people (2004) to more than 6000 people (2011).
Under this act, all Taiwanese rare disease sufferers are
eligible to get at least 70 % reimbursement. Whereas
for low-income citizens, they can receive 100 % reim-
bursement of actual orphan drugs and nutritional sup-
plements expenses [38]. SEA countries can adopt and
adapt the Rare Disease Control and Orphan Drug Act
of Taiwan which control their listing of covered orphan
drugs and implement medical subsidies for patients
with rare diseases [39].
There is potential to organise a multi-stakeholder and
multi-country approach and strategy to manage rare
diseases efficiently
Management of rare disease should highlight the neces-
sity comparable with other common diseases in term of
treating rare disease sufferers, sharing information of
registries, competencies, advocacy and awareness of the
disease. Improvement of all these issues should be driven
by all parties especially the government, economic realities,
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political support, clinical expertise, industry as well as pa-
tient activism towards better patient outcomes (Fig. 2).
There are possibilities for SEA to improve cross border
cooperation in rare disease support for instance free flow
of goods, services, investment or capital and skilled labour.
With all six initiatives, it can develop a regional model for
rare disease to support rare disease registry, genetic data-
base, training, education, awareness besides saving time
and costs. Few incremental steps and focus actions are
recommended and should be taken by Association of SEA
Nations (ASEAN) towards comprehensive rare disease
treatment and funding (Table 2).
Nevertheless, the most important is the partnerships
with government, policymakers, clinician, patient sup-
port groups and industry within and even between coun-
tries. Hopefully, these suggestions can be adopted and
address some of the problems or issues in managing rare
diseases and orphan drugs access.
Conclusion
Generally, Southeast Asian countries have made signifi-
cant progress in the management of rare disease, but
there remain key areas for substantial development op-
portunities. We offer the following short and medium-
term suggestions with the underpinning belief that a
country’s progress of rare disease management is in
parallel with the development of its universal healthcare
system and infrastructure.
In the short term, focus countries should understand
and leverage best practices and established approaches
from around the world. In rare disease management,
countries typically take a similar journey and thus there
is no need to reinvent the wheel. More importantly,
while best practice countries are relatively wealthy,
many of them show it is not a prerequisite to building
out rare disease management. Additionally, focus coun-
tries should support and leverage patient support and
Fig. 1 Rare disease journey-Progress of SEA and benchmark countries
Fig. 2 Rare disease framework-identifying stakeholders, support and measures of success
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advocacy groups. Highlighting the case for rare disease
sufferers will help with sensitivity and understanding
across different stakeholders. It will also move the nee-
dle forward on a comprehensive rare disease national
strategy and legislation, including efforts for public and
private funding.
In the medium term, it is crucial for the region turn
to information sharing, partnerships, and ultimately a
regional model. Each country might not have enough
resources or even patients to tackle rare disease man-
agement. However, scale exists in aggregate to develop
initiatives and share expertise, medicines, and technol-
ogy. One-step could be to establish an ASEAN-wide
rare disease network made up of clinicians, healthcare
policymakers and advocacy groups. In addition, similar
to the establishment of Rainbow Across Borders organ-
isation, the region should continue region-wide patient
advocacy for rare disease patients and increase aware-
ness. Another incremental step should be centred on
clinical services for consistency. Countries on a national
and regional level should develop standardised treatment
guidelines, identify and invest in centres of excellence, es-
tablish compatible national patient registries, enable infor-
mation sharing as well as improve regional sourcing of
drugs for greater purchasing power. Finally, research con-
sortiums could be developed for greater efficiency. This
should include increased funding for research into rare
diseases and a creation of a genetic database to collect in-
formation from rare disease sufferers.
Ultimately, if the focus countries work together to
manage rare diseases, the region will see an improve-
ment of patient outcomes through better funding and
community support, leading to a better understanding of
rare disease patient needs and how to improve their
daily experiences. This in turn will also improve the
overall healthcare landscape of Southeast Asia.
Limitations of the study
Public information and industry and statistical data are
from sources we deem to be reliable based on current data
and historical trends. Information from communications
and interviews are assumed reliable. Any such predictions
are subject to inherent risks and uncertainties.
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